세계의 과민성 방광 치료 시장 보고서(2025년)
Overactive Bladder Treatment Global Market Report 2025
상품코드 : 1821691
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

과민성 방광 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 5.2%를 나타낼 것으로 예측되고 39억 7,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 고령화 인구, 고급 치료법, 맞춤형 의약품, 의료 투자, 환자 중심 치료에 기인할 수 있습니다. 예측 기간의 주요 동향에는 비약물적 중재, 디지털 헬스 솔루션, 대체 의학 수용, 성별 맞춤형 접근법, 그리고 통합적 치료가 포함됩니다.

향후 5년간 5.2% 성장이라는 전망치는 이전 예측 대비 0.1% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 인상으로 아일랜드와 일본에서 원산지인 항콜린제 및 천골 신경 조절 장치의 가격이 상승하여 미국 환자들의 치료비 부담이 촉진될 전망입니다. 이는 치료 비용 증가와 고급 비뇨기과 치료 접근성 제한으로 이어질 것입니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 파급 효과는 더욱 확대될 것입니다.

과민성 방광 치료 시장 시장은 고령 인구 증가가 성장세를 촉진함에 따라 성장할 전망입니다. 65세 이상 노인 인구는 요류 감소, 과민성 방광, 전립선 비대증, 신장 결석 등의 요인으로 요로 감염에 더 취약해 과민성 방광 증상 치료에 대한 수요가 높아지고 있습니다. ReliefWeb이 2022년 7월에 보고한 것처럼 65세 이상의 세계 인구는 2022년의 10%에서 2050년에 16%를 나타낼 것으로 예측되고 증가했으며 2050년에 총 인구의 23%를 차지하는 9,400만 명에 달할 것으로 예측됩니다. 따라서 노인 인구의 확대는 과민성 방광 치료 시장의 성장을 가속하는 중요한 요소입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Overactive bladder encompasses a range of symptoms that can impact a person's frequency of urination and the sense of urgency. Treatment involves modifying specific behaviors, incorporating pelvic floor muscle exercises, and other measures aimed at alleviating symptoms. The objective of treatment is to effectively address the symptoms of an overactive bladder and decrease instances of urgent incontinence.

The primary categories of diseases in the treatment of overactive bladder are idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity involves an involuntary contraction of the bladder muscle, leading to a sudden and urgent urge to urinate. This condition is managed through overactive bladder (OAB) treatment methods, including anticholinergics and beta-3 agonists. Various therapies such as anticholinergics, mirabegron, neurostimulation, intravesical instillation, and other approaches are employed to treat these diseases. These therapies are available through channels such as hospital pharmacies, drug stores, retail pharmacies, and online providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The overactive bladder treatment market research report is one of a series of new reports from The Business Research Company that provides overactive bladder treatment market statistics, including overactive bladder treatment industry global market size, regional shares, competitors with an overactive bladder treatment market share, detailed overactive bladder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the overactive bladder treatment industry. This overactive bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The overactive bladder treatment market size has grown steadily in recent years. It will grow from $3.15 billion in 2024 to $3.24 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to medication development, patient awareness, demographic shifts, clinical guidelines, investment in research.

The overactive bladder treatment market size is expected to see strong growth in the next few years. It will grow to $3.97 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging population, advanced therapies, personalized medicine, healthcare investments, patient-centric care. Major trends in the forecast period include non-pharmacological interventions, digital health solutions, alternative medicine acceptance, gender-specific approaches, and holistic care.

The forecast of 5.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of anticholinergic medications and sacral neuromodulation devices sourced from Ireland and Japan, exacerbating treatment costs and limiting access to advanced urologic care. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The overactive bladder treatment market is poised for growth, driven by the increasing elderly population. With the geriatric demographic, encompassing individuals aged 65 and older, being more susceptible to urinary tract infections due to factors such as diminished urine flow, overactive bladder, enlarged prostate, or kidney stones, there is a heightened demand for treatments targeting overactive bladder symptoms. As reported in July 2022 by ReliefWeb, the global population aged 65 and older is projected to rise from 10% in 2022 to 16% in 2050, reaching 94 million individuals, constituting 23% of the total population by 2050. Thus, the expanding geriatric population is a key factor propelling the overactive bladder treatment market's growth.

The prevalence of bladder cancer is another significant driver for the growth of the overactive bladder treatment market. Bladder cancer, characterized by abnormal cell growth in the bladder, often manifests with symptoms of overactive bladder. Treating these symptoms is crucial for improving the quality of life for individuals with bladder cancer. According to the American Society of Clinical Oncology's estimation in March 2023, around 82,290 adults in the United States are anticipated to be diagnosed with bladder cancer, with approximately 16,710 deaths expected in 2023. This underscores the correlation between bladder cancer and the prevalence of overactive bladder, contributing to the market's growth.

A notable trend in the overactive bladder treatment market is the approval of new products. Leading companies in the market are investing in the development of advanced products that incorporate the latest technologies to maintain their market positions. For example, in April 2023, Avation Medical Inc., a US-based company specializing in advanced neuromodulation and digital health, received FDA clearance for The Vivally System. This non-invasive bladder control therapy device, along with its accompanying mobile application, is designed to treat individuals suffering from urge urinary incontinence and urine urgency linked to overactive bladder syndrome. The system combines an ankle-worn garment with an intelligent controller, delivering personalized neuromodulation energy to the tibial nerve.

Major companies in the overactive bladder (OAB) treatment market are concentrating on developing innovative, cost-effective solutions to lower healthcare expenses and enhance patient adherence. Cost-effective solutions deliver favorable results or achieve their intended objectives at a lower cost than alternatives. For example, in April 2024, Zydus Lifesciences Ltd., an India-based pharmaceutical firm, launched a generic drug for managing OAB, which is characterized by urinary urgency, frequency, and incontinence. This new generic medication, now available in the US market, offers a cost-effective extended-release option. While anticholinergic drugs have traditionally been used to treat OAB, newer therapies are emerging, and the introduction of generics helps reduce healthcare costs and promotes better patient adherence to treatment.

In January 2024, Boston Scientific, a US-based medical technology company, announced its agreement to acquire Axonics Inc. for $3.7 billion. This acquisition enhances Boston Scientific's portfolio in the neuromodulation market, allowing the company to broaden its offerings and improve patient outcomes. By integrating Axonics' advanced technologies, Boston Scientific intends to strengthen its capabilities in delivering comprehensive solutions for patients with urological and gastrointestinal conditions. Axonics Inc., also based in the US, specializes in developing innovative sacral neuromodulation solutions for treating bladder and bowel dysfunction.

Major companies operating in the overactive bladder treatment market include AbbVie Inc., Astellas Pharma Inc., Laborie Medical Technologies Corporation, Endo International plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services Inc., Medtronic plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, Cogentix Medical Inc., Dr. Reddy's Laboratories Ltd., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Merck & Co. Inc., Macleods Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Novartis International AG, Daiichi Sankyo Company ltd., Boston Scientific Corporation, Grunenthal GmbH, Collegium Pharmaceutical Inc.

North America was the largest region in the overactive bladder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the overactive bladder treatment market report during the forecast period. The regions covered in the overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the overactive bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The overactive bladder treatment market consists of revenues earned by entities by providing treatments such as behavioral therapies, nerve stimulation, and percutaneous tibial nerve stimulation (PTNS). The market value includes the value of related goods sold by the service provider or included within the service offering. The overactive bladder treatment market also includes sales of medications used in providing overactive bladder treatment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Overactive Bladder Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on overactive bladder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for overactive bladder treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The overactive bladder treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Overactive Bladder Treatment Market Characteristics

3. Overactive Bladder Treatment Market Trends And Strategies

4. Overactive Bladder Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Overactive Bladder Treatment Growth Analysis And Strategic Analysis Framework

6. Overactive Bladder Treatment Market Segmentation

7. Overactive Bladder Treatment Market Regional And Country Analysis

8. Asia-Pacific Overactive Bladder Treatment Market

9. China Overactive Bladder Treatment Market

10. India Overactive Bladder Treatment Market

11. Japan Overactive Bladder Treatment Market

12. Australia Overactive Bladder Treatment Market

13. Indonesia Overactive Bladder Treatment Market

14. South Korea Overactive Bladder Treatment Market

15. Western Europe Overactive Bladder Treatment Market

16. UK Overactive Bladder Treatment Market

17. Germany Overactive Bladder Treatment Market

18. France Overactive Bladder Treatment Market

19. Italy Overactive Bladder Treatment Market

20. Spain Overactive Bladder Treatment Market

21. Eastern Europe Overactive Bladder Treatment Market

22. Russia Overactive Bladder Treatment Market

23. North America Overactive Bladder Treatment Market

24. USA Overactive Bladder Treatment Market

25. Canada Overactive Bladder Treatment Market

26. South America Overactive Bladder Treatment Market

27. Brazil Overactive Bladder Treatment Market

28. Middle East Overactive Bladder Treatment Market

29. Africa Overactive Bladder Treatment Market

30. Overactive Bladder Treatment Market Competitive Landscape And Company Profiles

31. Overactive Bladder Treatment Market Other Major And Innovative Companies

32. Global Overactive Bladder Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Overactive Bladder Treatment Market

34. Recent Developments In The Overactive Bladder Treatment Market

35. Overactive Bladder Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기